post-traumatic stress disorder

TCS 1102 is an effective, dual orexin receptor antagonist (Ki: 0.2/3 nM for OX2/1 receptors).

Vofopitant (GR 205171) is a potent NK1 receptor antagonist with anxiolytic and antiemetic activity for the study of post-traumatic stress disorder (PTSD).

5-HT2A agonist 4 (Compound 70) is a 5-HT2A agonist with an EC50 value of 0.30 nM for h5-HT2A. It can be utilized in research related to depression, substance addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain.

5-HT2A agonist 3 (Compound P-141) is a selective agonist of the 5-hydroxytryptamine 2A receptor (5-HT2A) with an EC50 value of 13.80 nM. It shows potential for use in research on mental disorders such as depression, post-traumatic stress disorder, obsessive-compulsive disorder, and other central nervous system-related conditions.

5-HT2A agonist 5 (Compound 88) is a 5-HT2A agonist with an EC50 of 0.01 nM for h5-HT2A. It can be utilized in research concerning depression, drug addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain.

5-HT2C agonist-11 (Compound 1) is an orally active, brain-penetrant, and selective 5-HT2C receptor agonist with an EC50 of 15 nM. It activates the Gq protein signaling pathway, promoting intracellular calcium release. This compound shows potential for research in depression, post-traumatic stress disorder (PTSD), and neuropathic pain.

5-HT2A agonist 6 (compound 2-6) is a 5-HT2A receptor agonist with an EC50 of 1.7 nM. It is applicable in studies of stress-related disorders, including depression, anxiety, and post-traumatic stress disorder.

Emapunil (XBD-173) is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO.

SSR411298 is a reversible, orally active compound that selectively inhibits fatty acid amide hydrolase (FAAH). Its potential lies in the field of post-traumatic stress disorder (PTSD) research.

BRD3731 is a selective inhibitor of GSK3β, demonstrating an IC50 value of 15 nM for GSK3β and 215 nM for GSK3α. Due to its inhibitory properties, BRD3731 holds promise for investigating various medical conditions, including post-traumatic stress disorder (PTSD), psychiatric disorders, diabetes, and neurodegenerative disorders [1].

Fluvoxamine acid is a medication which functions as a selective serotonin reuptake inhibitor (SSRI) and σ1 receptor agonist. Fluvoxamine is used primarily for the treatment of obsessive-compulsive disorder (OCD), and is also used to treat major depressive disorder (MDD), and anxiety disorders such as panic disorder and post-traumatic stress disorder (PTSD).

Orexin Receptor Modulator-1 is a compound utilized in the study of various conditions including substance addiction, panic disorder, anxiety, post-traumatic stress disorder (PTSD), pain, depression, seasonal affective disorder (SAD), eating disorders, and hypertension [1].

5-HT2A&5-HT2C agonist-1 (Example 2) is a dual-acting agent targeting 5-HT2A and 5-HT2C receptors with IC50 values of 196 nM and 0.9 nM, respectively. It is applicable in studying central nervous system disorders, including depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headaches, post-traumatic stress disorder (PTSD), and seizure disorders [1].